Abstracts

154 – DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results

Background Trials in adults living with HIV have shown non-inferiority of dolutegravir (DTG) plus lamivudine (3TC) 2-drug regimen (DTG/3TC) compared to 3-drug regimens (3DR) for maintaining viral suppression. Data in children are limited. Methods D3 / Penta 21 was a non-inferiority 96-week trial evaluating efficacy and safety of DTG/3TC compared to DTG-based 3DR  (control) in…

155 – Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results

Background IMPAACT 2017 (MOCHA) evaluated the safety, tolerability, and pharmacokinetics (PK) of the first all-injectable long-acting (LA) antiretroviral therapy (ART) of intramuscular (IM) cabotegravir (CAB) + rilpivirine (RPV) in virologically suppressed (HIV-1 RNA <50 c/mL) adolescents with HIV. Data through Week 96 and end-of-study are presented. Methods In this Phase I/II noncomparative trial, virologically suppressed…

156 – Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention

Background Adolescents with perinatally-acquired HIV (APHIV) have lower retention and viral suppression rates during and after transitioning to adult care; interventions to support the transition process are needed. Methods We conducted a hybrid implementation-effectiveness, stepped-wedge, cluster-randomized trial to assess the effectiveness of in-person vs virtual adolescent-friendly transition interventions (InTSHA-VIP) on viral suppression (viral load <200…

157 – Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini

Background Human papilloma virus (HPV) vaccination protects against HPV-related disease outcomes like cervical cancer, but immune responses to vaccination among HIV positive (HIV+) persons may be compromised. We compared immunogenicity of 9-valent HPV vaccine (9vHPV) by HIV infection status in Eswatini.  Methods In this multi-site, open-label, non-inferiority study, three HIV+ cohorts received a 2-dose regimen…

164 – Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial

Background Urine tenofovir (TFV) and viral load (VL) assays performed at the point of care (POC) could improve HIV treatment outcomes, but have not been assessed together in randomized trials. We tested whether monthly POC urine TFV testing and biannual POC VL testing improved viral suppression and retention-in-care among people with HIV (PWH) initiating TFV-based…

166 – Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV

Background Broadly neutralizing antibodies (bNAbs) against HIV-1 are in active clinical development. While they exhibit potent antiviral activity, their impact on the autologous HIV immune response remains unclear. The kinetics of autologous functional antibody responses during bNAb therapy have not been studied, as therapeutic and endogenous antibody effects are difficult to separate. To address this,…

167 – Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure

Background Autologous neutralizing antibodies (aNAbs) block outgrowth of substantial but variable fraction of reservoir viruses in people with HIV (PWH), and in rare early treated PWH, aNAbs can prevent viral rebound following treatment interruption. Here we characterized the aNAb response at the clonal level in a representative PWH who started treatment during chronic infection. Methods…

168 – In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention

Background Broadly neutralizing antibodies (bNAbs) are promising therapies against HIV-1 but require repeated infusions, limiting use in low- and middle-income countries with high HIV prevalence. The helper-dependent adenovirus (HDAd) gene therapy platform offers an accessible strategy for long-term therapeutic delivery with a one-time vector infusion. We developed the HDAd 6/3+ vector system to transduce nonhuman…

169 – Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials

Background Broadly neutralizing antibodies (bnAbs) target conserved regions of HIV Env. In clinical practice, HIV rapidly evolves to escape bnAbs via distinct resistance pathways, as described in recent clinical trials. Here, we delineate virus escape from VRC07-523LS in viremic rhesus macaques (RM) infected with a SHIV encoding a clade C Env.  Methods In a study…